Joshua Fitch, Senior Editor

The Rare Pediatric Disease Designation from the FDA follows the previously granted Orphan Drug and Fast Track Designations.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Shreya Doshi, MBBS, FAAP, shares how routine screening appointments can serve as a good time to discuss environmental elements with families.

With no adverse events reported, findings suggested once-weekly PDL treatments are associated with improved outcomes and shorter treatment duration among children with effective PWB.

Shreya Doshi, MBBS, FAAP, discusses how contamination could be reducing your practice's recycling impact.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

Donna Hallas. PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, underscores the critical need for proper vaccination and effective communication between parents and schools to ensure sick children stay home, while addressing logistical challenges faced by parents.

A discussion on the importance of communication between healthcare providers, school personnel, families, and children in the administration and organization of medication in schools.

Shreya Doshi, MBBS, FAAP, joined us to discuss some easy opportunities to reduce emissions in your practice and help improve health care sustainability.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

Details of newly FDA-approved roflumilast cream 0.15% for AD in pediatric patients, plus insight and commentary from Lawrence Eichenfield, MD.

An intentional launch date for ustekinumab-ttwe in the United States is set for sometime in February 2025.

The decision target action date was July 7, 2024. At this time, there is no indication from the federal agency to extend the date further.

Annie Certo, MA, and AJ Harris, MS, break down what a “summer slump” is and how it can affect children during summer break from school. The duo offers suggestions on how to combat the negative associations of a “summer slump.”

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Brief but practical reminders to help prevent drowning in children from the perspective of an emergency medicine fellow.

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

Matthew M. Davis, MD, MAAP, breaks down a newly-published study highlighting a potential association between COVID-19 vaccination and prevalence of symptomatic childhood asthma.

A discussion evaluating how social media can impact an individual's mental health, and what specific elements of social media could be causing it.

FDA decisions for the 2 accepted NDAs have target action dates of December 29 and December 30, 2024, respectively.

The submission to the FDA includes data from the phase 2b ReNeu trial of patients aged 2 years and older with NF1-associated PN causing significant morbidity.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The primary endpoint of the study was to measure childhood stigma related to disease visibility.

New data for FDA-approved dupilumab (Dupixent; Regeneron and Sanofi) highlights positive study results for the eosinophilic esophagitis (EoE) treatment in children aged 1 to 11 years.

Shreya Doshi, MBBS, FAAP, explains what health care sustainability is and how the industry contributes to climate change.

"This decision will have serious health consequences for children and young people," stated the president of the American Academy of Pediatrics.

How providers can advocate for increased research determining social media and its association with youth mental health.

The decision makes pitolisant the first and only FDA-approved, non-scheduled treatment option for daytime sleepiness in this patient population.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

For ambulatory Duchenne patients, delandistrogene moxeparvovec-rokl was granted traditional approval, while accelerated approval was granted for non-ambulatory patients.